At a glance
ClinicalIndex Comparison RecordN/ACompleted· 105 enrolled
Drug / intervention
Ergocalciferol +2 moredrug
Likely dose
Ergocalciferol 50,000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
DIVINE: Dialysis Infection and Vitamin D In New England
In Brief
A clinical study evaluating Ergocalciferol and Placebo for End Stage Renal Disease. Completed, enrolled 105 participants across 3 sites.
Detailed Summary
Infection is the second-leading cause of death in individuals requiring dialysis treatment for kidney failure. New research suggests the high risk of infection may be due in part to low levels of vitamin D, which are extremely common in kidney disease. This study is designed to determine safe and effective ways to raise vitamin D levels while monitoring effects on the immune system.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Disease
CountriesUnited States
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartNov 2009
Primary CompletionOct 2014
TodayJul 2026
First PostedMay 4, 2009
Enrollment StartNov 1, 2009
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 17.2 years ago
Interventions
Ergocalciferoldrug
50,000 IU tablet given weekly
Ergocalciferoldrug
50,000 IU tablet given monthly
Placeboother
Placebo equivalent of ergocalciferol, given weekly as one tablet